Malignant Melanoma – Epidemiology – Emerging Markets Data
Clarivate Epidemiology’s coverage of malignant melanoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of malignant melanoma for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy for the major mature pharmaceutical markets.
Clarivate Epidemiology’s malignant melanoma forecast will answer the following questions:
- How will improvements in survival change the number of people diagnosed with malignant melanoma each year?
- How will the declining risk of recurrence change the number of people living with malignant melanoma?
- Of all people diagnosed with malignant melanoma, how many in of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of malignant melanoma over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph of the patient flow between or within different disease states for the countries considered in this report. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.
Clarivate Epidemiology provides at least 10 years of forecast data for the following malignant melanoma patient populations:
- Diagnosed incident cases by stage.
- Diagnosed prevalent cases by resectability status.
- Locoregional recurrence.
- Unresectable recurrence.
- First-line unresectable BRAF+ve and BRAF-ve drug-treatable population(s).
- Adjuvant BRAF+ve and BRAF-ve drug-treatable populations.
- Other lines of treatment.
… and many more (details available on request).
Note: Coverage may vary by country and region.
Table of contents
- Malignant Melanoma - Epidemiology - Emerging Markets Data
- Introduction
- Key Findings
- Incidence of Malignant Melanoma per Year per 100,000 People of All Ages in 2021 and 2031
- Incidence of Malignant Melanoma per Year per 100,000 People of All Ages in 2021 and 2031
- Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Malignant Melanoma Over the Next 10 Years
- Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Malignant Melanoma Over the Next 10 Years
- Analysis of Diagnosed Incident Cases of Malignant Melanoma in the Countries Under Study in 2021 by Stage at Diagnosis
- Analysis of Diagnosed Incident Cases of Malignant Melanoma in the Countries Under Study in 2021 by Stage at Diagnosis
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Surup Dey, M.L.T., M.P.H., is an epidemiologist at Clarivate. A former microbiologist, he was involved in the diagnosis of rare hematological disorders. Mr. Dey has a background in medical laboratory science from Christian Medical College in Vellore and earned a postgraduate degree in public health specializing in epidemiology from Manipal University. He specializes in real-world data analysis, cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer.
Swarali Tadwalkar, M.P.H., is a principal epidemiologist at Clarivate. Previously, she was involved in primary and secondary healthcare research, including projects in digital health, health policy and management, and health economics and outcomes research (HEOR). Ms. Tadwalkar also coordinated various nongovernmental public health projects focusing on access to treatment for hepatitis and human papilloma virus. She received her M.P.H. from the University of South Florida in Tampa.